Physician profile
Elisabete Sharp
NPI 1134433717
$3,513.48
in general payments reported to CMS, 2019-2025
29 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $147 · 2021: $47.87 · 2022: $427 · 2023: $420 · 2024: $542 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $522.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $372.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $344.60 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $207.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.01 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $145.05 | 2019-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $141.28 | 2019 | |
| Merck Sharp & Dohme LLC | $106.36 | 2019-2020 | |
| Abbvie INC. | $105.01 | 2019-2025 | Vraylar, Viberzi, Linzess |
| Abbott Laboratories | $89.57 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $87.56 | 2019-2020 | |
| Inspire Medical Systems, INC. | $74.92 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $72.53 | 2022 | |
| Sunovion Pharmaceuticals INC. | $48.61 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.66 | 2019 | |
| Astellas Pharma US INC | $33.45 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $31.14 | 2024 | Aptima |
| Idorsia Pharmaceuticals US INC | $27.80 | 2023 | Quviviq |
| Irhythm Technologies, INC. | $25.05 | 2024 | Zio Xt Patch, Zio Monitor |
| Exact Sciences Corporation | $19.32 | 2023 | Cologuard Collection Kit |
| Organon LLC | $18.27 | 2022 | |
| Phadia US INC. | $17.76 | 2024 | Immunocap |
| Amarin Pharma, INC. | $17.49 | 2019 | |
| Allergan, INC. | $17.01 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.02 | 2021 | |
| Daiichi Sankyo INC. | $14.97 | 2024 | Injectafer |
| Cranial Technologies, INC | $13.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisabete Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.